Singapore Tonight - Wed 9 Jul 2025
From business to politics, health to technology, we bring you up-to-date with the latest news on Singapore and analyze how these events may affect you tomorrow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
37 minutes ago
- Business Times
China Medical System shares surge 11% with its secondary listing on SGX
[SINGAPORE] Shares of China Medical System (CMS) jumped 6 per cent at the market open with its secondary listing made on the mainboard of the Singapore Exchange (SGX) on Tuesday (Jul 15). At 9 am, its shares traded at S$2.05 at the open, before increasing to S$2.08 by 9.03 am. By 9.05 am, CMS had risen by over 2.4 per cent to S$2.10, and hit S$2.12, up 3.4 per cent as at 9.07 am. As at 9.12 am, its share price had risen to S$2.18, 6.3 per cent higher than its price at market open. The company's shares were last at S$2.28, up 11.2 per cent with around 150,000 shares changing hands. In an earlier statement on Jun 24, CMS said the listing will not involve the issuance of new shares, and the shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. CMS is a specialty pharma with a focus on sales and marketing in China, with capabilities across the full lifecycle of drug development, from identifying clinical needs to research and development (R&D) regulatory approval, and commercialisation. The company has been listed in Hong Kong since 2010, and has expressed interest in a secondary listing on Singapore's bourse in July this year. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its regional headquarters for its South-east Asia and Middle East business is Singapore. According to CMS, it expects growth momentum to accelerate on the back of the replenishment of its pipeline of innovative drugs to about 40 products as at Dec 31, 2024, where it noted four key platforms to scale its pharmaceutical ecosystem across Asia-Pacific. One is CMS R&D, which is involved in drug discovery and development targeting global markets, while PharmaGend is a development and manufacturing platform for regional manufacturing and supply. The pharmaceutical group also has Rxilient Health, a Singapore-headquartered entity focused on registration and commercialisation in South-east Asia and a Singapore venture arm, which makes strategic investments to support regional pharma innovation.
Business Times
an hour ago
- Business Times
China Medical System surges 6% at the open with its secondary listing on SGX
[SINGAPORE] Shares of China Medical System (CMS) jumped 6 per cent at market open with its secondary listing made on the mainboard of the Singapore Exchange (SGX) on Tuesday (Jul 15). At 9 am, its shares began trading at 2.06 Chinese yuan (CNY), before increasing to 2.08 CNY by 9.03 am. By 9.05 am, CMS had risen by over 4.8 per cent to 2.10 CNY, and hit 2.12 CNY, up 6 per cent as at 9.07 am. The company's shares were last at 2.28 CNY, with around 150,000 shares changing hands. In an earlier statement on Jun 24, CMS said the listing will not involve the issuance of new shares, and the shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. CMS is a specialty pharma with a focus on sales and marketing in China, with capabilities across the full lifecycle of drug development, from identifying clinical needs to research and development (R&D) regulatory approval, and commercialisation. The company has been listed in Hong Kong since 2010, and has expressed interest in a secondary listing on Singapore's bourse in July this year. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its regional headquarters for its South-east Asia and Middle East business is Singapore. According to CMS, it expects growth momentum to accelerate on the back of the replenishment of its pipeline of innovative drugs to about 40 products as at Dec 31, 2024, where it noted four key platforms to scale its pharmaceutical ecosystem across Asia-Pacific. One is CMS R&D, which is involved in drug discovery and development targeting global markets, while PharmaGend is a development and manufacturing platform for regional manufacturing and supply. The pharmaceutical group also has Rxilient Health, a Singapore-headquartered entity focused on registration and commercialisation in South-east Asia and a Singapore venture arm, which makes strategic investments to support regional pharma innovation.
CNA
an hour ago
- CNA
CNA938 Rewind - Stock take today: Markets complacent or taking a breather?
CNA938 Rewind - Q2 growth: Could we be in for a tougher second half? According to advance estimates from the Ministry of Trade and Industry, Singapore's economy grew 4.3 per cent in the second quarter of 2025 - faster than the 4.1 per cent growth in the first quarter of the year. But the ministry flagged significant uncertainty and downside risks remaining in the global economy in the second half of the year - given the lack of clarity over U.S tariff policies. Lance Alexander discusses with Selena Ling, Chief Economist and Head of Global Markets Research and Strategy, OCBC.
